Nektar Therapeutics expected to post a loss of $3.03 a share - Earnings Preview

Nektar Therapeutics

05/08/2025 21:19

Nektar Therapeutics NKTR.OQ NKTR.O is expected to  show a fall in quarterly revenue when it reports  results on August 7 for the period ending June 30 2025

The San Francisco California-based  company is expected to report a 53.8% decrease in revenue to $10.849 million from $23.49 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Nektar Therapeutics is for a loss of $3.03 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Nektar Therapeutics is $95.00, about 75.5% above its last closing price of $23.27

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-2.39
-2.46
-3.60
Missed
-46.1
Dec. 31 2025
-2.71
-2.52
-2.40
Beat
4.9
Sep. 30 2024
-3.34
-3.16
-2.70
Beat
14.6​
Jun. 30 2024
-3.08
-3.05
-3.75
Missed
-22.8
​​Mar. 31 2024
-2.88
-2.85
-2.85
Met
0
Dec. 31 2023
-3.35
-3.19
-3.30
Missed
-3.6​
Sep. 30 2023
-3.15
-2.99
-3.60
Missed
-20.3
Jun. 30 2023
-4.71
-4.26
-4.05
Beat
4.9

This summary was machine generated August 5 at 20:19 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)